NEW YORK (GenomeWeb) – Fluidigm said after the close of the market on Thursday that it has formed a strategic partnership with Ascendas Genomics to develop molecular diagnostics in China.

Under the agreement, Ascendas will develop and commercialize molecular diagnostic systems and assays using microfluidic technologies included in Fluidigm's Biomark HD and Juno systems.

Fluidigm's platforms enable scalable and automated workflows for quantitative PCR, gene expression, copy number variation analysis, and next-generation sequencing library preparation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.